FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Effectiveness of a community-based multicomponent lifestyle intervention (the ADA programme) to improve the quality of life of French breast cancer survivors: protocol for a pragmatic cluster randomised trial and embedded qualitative study. PMID 38485475 · BMJ Open · 2024-Mar-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of timing and format of patient decision aids for breast cancer patients on their involvement in and preparedness for decision making - the IMPACTT randomised controlled trial protocol. PMID 38475758 · BMC Cancer · 2024-Mar-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| [The long-term efficacy of metformin in megestrol acetate-based fertility-sparing treatment for patients with endometrial atypical hyperplasia and endometrioid endometrial cancer]. PMID 38462352 · Zhonghua Yi Xue Za Zhi · 2024-Mar-12 The study is an eligible RCT with drug intervention and time-to-event endpoints in human endometrial cancer. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III, which is a required criterion for inclusion. Therefore, is_eligible is set to false. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). PMID 38232337 · J Clin Oncol · 2024-Mar-10 The record describes a randomized trial with a drug intervention and a primary time-to-event endpoint (DFS). The phase is not explicitly stated in the metadata but is definitively identified as a randomized trial with results, which aligns with the criteria for a definitive randomized trial. The report is an original primary result. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. PMID 38096462 · J Clin Oncol · 2024-Mar-10 Eligibility is indeterminate because the required Phase III/IIIb or Phase II/III evidence is not explicitly established in the provided record. All other criteria are met. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial. PMID 38458809 · BMJ Open · 2024-Mar-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect and safety of electroacupuncture on weight loss in obese patients with pre-diabetes: study protocol of a randomised controlled trial. PMID 38458786 · BMJ Open · 2024-Mar-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. PMID 38539415 · Cancers (Basel) · 2024-Mar-07 This is a real-world retrospective analysis, not a randomized controlled trial. The abstract describes a non-randomized, retrospective cohort study analyzing clinical outcomes in patients treated with osimertinib in routine clinical practice. It references the FLAURA trial but does not present new randomized data from that trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Statistical analysis plan for the PRO B study: open-label, superiority randomised controlled trial of alarm-based patient-reported outcome monitoring in patients with metastatic breast cancer. PMID 38448904 · Trials · 2024-Mar-07 The record is a statistical analysis plan (SAP) for a randomized trial, not an original result report. The intervention is non-drug (PRO monitoring). While the trial is randomized and oncology, and the primary outcome is a quality-of-life score (not a standard time-to-event efficacy endpoint like OS/PFS), the key exclusion criteria are the lack of a drug intervention and the non-result report type. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial. PMID 38123994 · Gut · 2024-Mar-07 The study is a randomized trial in oncology (HCC) with a time-to-event endpoint (OS). However, it fails two key eligibility criteria: 1) The intervention is a comparison between a non-drug procedure (endoscopic variceal ligation) and a drug (propranolol), not a drug-containing intervention against a control (or another drug). 2) The trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided record. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study. PMID 38630878 · J Bone Miner Res · 2024-Mar-04 The study is a randomized controlled trial evaluating the bone health effects of adjuvant zoledronate in breast cancer patients. It is oncology-related, human, randomized, and involves a drug intervention. However, the primary endpoint is bone mineral density and bone turnover markers, not a time-to-event efficacy endpoint like OS, PFS, DFS, or HR. Therefore, it does not meet the required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. PMID 38536173 · JAMA Netw Open · 2024-Mar-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial. PMID 37812679 · Oncologist · 2024-Mar-04 The report is a subgroup analysis (Black patients) from the ARASENS trial. While it describes a randomized, oncology drug trial with time-to-event endpoints, it does not represent the primary/original result report of the overall trial. Furthermore, the abstract does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III, which is required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer. PMID 38430405 · Cancer Immunol Immunother · 2024-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial. PMID 38265821 · JAMA Dermatol · 2024-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial. PMID 38206631 · JAMA Oncol · 2024-Mar-01 The study is an oncology randomized clinical trial with a drug intervention, but it is not eligible because the phase is not established as Phase III/IIIb or Phase II/III, and the primary efficacy endpoint is not a time-to-event outcome (Kaplan-Meier or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of recovery profiles between total intravenous anaesthesia with propofol or remimazolam reversed with flumazenil in patients undergoing breast surgery: A randomised controlled trial. PMID 38205822 · Eur J Anaesthesiol · 2024-Mar-01 The record is a randomized controlled trial involving a drug intervention in an oncology surgical context, but it is an anesthesiology study focused on recovery profiles, not a Phase III/IIIb or Phase II/III randomized trial evaluating a drug-containing intervention for cancer treatment with a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial. PMID 38127335 · JAMA Oncol · 2024-Mar-01 The record meets all criteria except explicit confirmation of the trial phase. The abstract does not state Phase III, IIIb, or II/III. Publication types do not include phase information. Without explicit phase metadata, eligibility cannot be confirmed, but all other required criteria are satisfied. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Diet Matters in Breast Cancer Prognosis: Clinical Trial Evidence and Questions. PMID 38117468 · Clin Cancer Res · 2024-Mar-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial. PMID 37847493 · Clin Cancer Res · 2024-Mar-01 The study is a randomized controlled trial in human oncology with a time-to-event endpoint, but the intervention is a dietary program, not a drug-containing intervention. Phase information is not explicitly stated in the provided metadata to confirm it as a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy. PMID 37776979 · Int J Radiat Oncol Biol Phys · 2024-Mar-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Racecadotril Versus Loperamide in Acute Radiation Enteritis: A Randomized, Double-Masked, Phase 3, Noninferiority Trial. PMID 37742773 · Int J Radiat Oncol Biol Phys · 2024-Mar-01 The study is a randomized Phase III trial in oncology patients, but it evaluates supportive care drugs (Racecadotril vs. Loperamide) for managing a treatment side effect (radiation enteritis). The primary endpoint is a binary clinical response at 48 hours, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, RFS, TTP) measured with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the core eligibility criterion for a time-to-event efficacy endpoint in the context of anticancer drug trials. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pilot Trial on Ischemic Conditioning of the Gastric Conduit in Esophageal Cancer: Feasibility and Impact on Anastomotic Leakage (TIGOAL-I). PMID 38883947 · Ann Surg Open · 2024-Mar The study is a pilot RCT for esophageal cancer surgery, focusing on procedural feasibility and complication rates, not on a definitive phase or drug-based time-to-event efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of an Arsenic Mitigation Program on Arsenic Exposure in American Indian Communities: A Cluster Randomized Controlled Trial of the Community-Led Strong Heart Water Study Program. PMID 38534131 · Environ Health Perspect · 2024-Mar The study is not an oncology trial; it is a public health prevention study on arsenic exposure reduction in a population with cancer risk factors. It lacks a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nomogram for predicting pathological response to neoadjuvant treatment in patients with locally advanced gastric cancer: Data from a phase III clinical trial. PMID 38523553 · Cancer Med · 2024-Mar The study is a secondary analysis (nomogram development) from a Phase III trial, with pathological response as the primary endpoint, not the primary time-to-event efficacy endpoint required for inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT. PMID 38512064 · Health Technol Assess · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Identification of prognostic factors and construction of nomogram to predict cancer-specific survival for patients with ovarian granulosa cell tumors. PMID 38507268 · Cancer Rep (Hoboken) · 2024-Mar This is a retrospective, prognostic nomogram study based on SEER database data. It is not a randomized trial comparing therapeutic interventions. Although it includes a time-to-event outcome (cancer-specific survival) and is labeled 'Randomized Controlled Trial' in publication types, this refers only to the data split for model training/testing, not a trial of a drug intervention. It does not meet the core criteria of being a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Longitudinal Costs of Image-Guided Intensity-Modulated Radiation Therapy Versus Three-Dimensional Conformal Radiation: Lessons From Phase III PARCER Trial for Shaping Resource-Stratified Guidelines in Low- and Middle-Income Countries. PMID 38484193 · JCO Glob Oncol · 2024-Mar This is a secondary analysis of the Phase III PARCER trial focusing on economic and safety outcomes (cost implications, adverse events, toxicity management) of radiation therapy techniques. It does not report primary or key secondary time-to-event efficacy endpoints (OS, PFS, DFS, etc.) with Kaplan-Meier estimates or hazard ratios. The intervention is radiation therapy, not a drug-containing regimen. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial. PMID 38469377 · ERJ Open Res · 2024-Mar The trial is a Phase II randomized controlled trial in community-acquired pneumonia (non-oncology) with a drug intervention and a time-to-event primary endpoint, but it does not meet the core oncology eligibility requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy. PMID 38449916 · Open Forum Infect Dis · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. PMID 38445914 · J Gastrointest Surg · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. PMID 38423866 · Clin Ther · 2024-Mar The study is a randomized, open-label, bioavailability/bioequivalence/food-effect study of niraparib in advanced solid tumors. While it meets criteria for oncology, human subjects, randomization, and drug intervention, it is not a Phase III/IIIb or Phase II/III efficacy trial. The primary endpoint is pharmacokinetic (Cmax, AUC) and safety, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. PMID 38423047 · Lancet Oncol · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial). PMID 38413420 · Cardiovasc Intervent Radiol · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial. PMID 38387404 · EBioMedicine · 2024-Mar The report is an original, randomized, oncology trial with a drug intervention and time-to-event endpoints, but it is a post-hoc biomarker subgroup analysis, not the primary efficacy report. Additionally, the trial phase is not explicitly confirmed in the provided metadata. Therefore, it does not meet the inclusion criteria for a primary formal-result report of a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Treatment of localized hepatocellular carcinoma: resection vs. ablation vs. radiation. PMID 38373778 · Ann Palliat Med · 2024-Mar The provided record appears to be a review article or a synthesis discussing multiple treatment modalities for hepatocellular carcinoma, not the original formal results of a single randomized controlled trial. The phase of any underlying trial is not explicitly confirmed in the metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study Protocol for the Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence (SISTER) study: a community engaged national randomized trial. PMID 38348827 · J Comp Eff Res · 2024-Mar 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Peri-operative individually tailored psychological intervention in breast cancer patients improves psychological indices and molecular biomarkers of metastasis in excised tumors. PMID 38346596 · Brain Behav Immun · 2024-Mar The study is a randomized controlled trial in breast cancer patients but fails multiple eligibility criteria: the trial phase is not specified and cannot be assumed to be Phase III/IIIb or Phase II/III; the intervention is purely psychological with no drug component; and the primary endpoints are psychological scores and molecular biomarker changes, with no time-to-event efficacy endpoint reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study. PMID 38335565 · Thromb Res · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). PMID 38329052 · J Urol · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an 18F-FDG PET/CT-based radiomics nomogram. PMID 38315193 · Abdom Radiol (NY) · 2024-Mar The record describes a retrospective study developing a diagnostic radiomics nomogram. It is randomized only in the sense of splitting data into training/validation sets, not a therapeutic randomized controlled trial. It lacks a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outpatient management of cancer-associated pulmonary embolism: A post-hoc analysis from the HOME-PE trial. PMID 38308882 · Thromb Res · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. PMID 38307806 · Eur Urol Focus · 2024-Mar The study is a human, randomized, oncology trial with a drug intervention and time-to-event endpoints, but the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided information, preventing eligibility confirmation. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol. PMID 38302299 · J Geriatr Oncol · 2024-Mar 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Risk factors for abdominal surgical infectious complications after distal gastrectomy for gastric cancer: A post-hoc analysis of a randomized controlled trial (JCOG0912). PMID 38290246 · Eur J Surg Oncol · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab. PMID 38280181 · Oncol Ther · 2024-Mar This is a case report describing a single patient's long-term outcome from the IMpower133 trial. It is not the formal, primary or secondary result publication of the randomized trial itself. While it references the trial, it does not present the trial's aggregate efficacy results with time-to-event endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. PMID 38271746 · Eur J Cancer · 2024-Mar This is an original, formal result report of a Phase III randomized trial in human melanoma (oncology) with a drug-containing intervention (ipilimumab plus nivolumab) and a primary time-to-event efficacy endpoint (overall survival with Kaplan-Meier estimates). The 7-year follow-up data represent the final long-term primary analysis of the trial. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design. PMID 38264869 · Future Oncol · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. PMID 38242982 · Nat Med · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. PMID 38237621 · Lancet Gastroenterol Hepatol · 2024-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |